Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-6bf8c574d5-mggfc Total loading time: 0 Render date: 2025-02-22T08:15:40.847Z Has data issue: false hasContentIssue false

Apomorphine Hydrochloride Subcutaneous Infusion

Published online by Cambridge University Press:  20 February 2025

K. Ray Chaudhuri ,
Peter Jenner ,
Valentina Leta ,
Shelley Jones  and
Iro Boura
K. Ray Chaudhuri
Affiliation:
King's College London
Peter Jenner
Affiliation:
King's College London
Valentina Leta
Affiliation:
King's College London
Shelley Jones
Affiliation:
King's College London
Iro Boura
Affiliation:
St. George General Hospital of Chania, Crete, Greece
Get access

Summary

Apomorphine hydrochloride (6aβ-aporphine-10,11-diol hydrochloride hemihydrate; (R)-10,11-dihydroxy-6a-aporphine hydrochloride hemihydrate; (6aR)-5,6,6a,7-tetrahydro-6-methyl-4H-dibenzo[de,g]quinoline-10,11-diol hydrochloride hemihydrate) has a molecular weight of 303.8 and a molecular formula of C17H18ClNO2.

Type
Chapter
Information
The Movement Disorders Prescriber's Guide to Parkinson's Disease , pp. 30 - 39
Publisher: Cambridge University Press
Print publication year: 2025

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Suggested Reading

Carbone, F, Djamshidian, A, Seppi, K, Poewe, W. Apomorphine for Parkinson’s disease: efficacy and safety of current and new formulations. CNS Drugs 2019; 33(9): 905–918. doi: 10.1007/s40263-019-00661-z. PMID: 31473980; PMCID: PMC6776563.CrossRefGoogle ScholarPubMed
Katzenschlager, R, Poewe, W, Rascol, O, Trenkwalder, C, Deuschl, G, Chaudhuri, KR, Henriksen, T, van Laar, T, Spivey, K, Vel, S, Staines, H, Lees, A. Apomorphine subcutaneous infusion in patients with Parkinson’s disease with persistent motor fluctuations (TOLEDO): a multicentre, double-blind, randomised, placebo-controlled trial. Lancet Neurol 2018; 17(9): 749–759. doi: 10.1016/S1474-4422(18)30239-4. Epub 2018 Jul 25. PMID: 30055903.CrossRefGoogle Scholar
Titova, N, Chaudhuri, KR. Apomorphine therapy in Parkinson’s and future directions. Parkinsonism Relat Disord 2016; 33(Suppl 1): S56–S60. doi: 10.1016/j.parkreldis.2016.11.013. Epub 2016 Nov 30. PMID: 27913125.CrossRefGoogle ScholarPubMed

References

AHFS Drug information 2012. Bethesda: American Society of Health-System Pharmacists. Accessed on 5 December 2022 via www.medicinescomplete.com.Google Scholar
Apomorphine. In: Brayfield, A (Ed.), Martindale: The Complete Drug Reference. London: The Royal Pharmaceutical Society of Great Britain. Accessed on 5 December 2022 via www.medicinescomplete.com.Google Scholar
Apomorphine. In: DRUGDEX® System (electronic version). Truven Health Analytics, Greenwood Village, Colorado, USA. Accessed on 5 December 2022 via www.micromedexsolutions.com.Google Scholar
Auffret, M, Drapier, S, Vérin, M. Pharmacological insights into the use of apomorphine in Parkinson’s disease: clinical relevance. Clin Drug Investig 2018; 38(4): 287–312.CrossRefGoogle ScholarPubMed
Chaudhuri, KR, Leta, V. Apomorphine infusion for improving sleep in Parkinson’s disease. Lancet Neurol 2022; 21(5): 395–398.CrossRefGoogle ScholarPubMed
Chaudhuri, KR, Todorova, A, Nirenberg, MJ, Parry, M, Martin, A, Martinez-Martin, P, Rizos, A, Henriksen, T, Jost, W, Storch, A, Ebersbach, G, Reichmann, H, Odin, P, Antonini, A. A pilot prospective, multicenter observational study of dopamine agonist withdrawal syndrome in Parkinson’s disease. Mov Disord Clin Pract 2015; 2(2): 170–174.CrossRefGoogle Scholar
Dafsari, HS, Martinez-Martin, P, Rizos, A, Trost, M, dos Santos Ghilardi, MG, Reddy, P, Sauerbier, A, Petry-Schmelzer, JN, Kramberger, M, Borgemeester, RWK, Barbe, MT, Ashkan, K, Silverdale, M, Evans, J, Odin, P, Fonoff, ET, Fink, GR, Henriksen, T, Ebersbach, G, … Ray Chaudhuri, K ; EUROPAR and the International Parkinson and Movement Disorders Society Non-Motor Parkinson’s Disease Study Group. EuroInf 2: subthalamic stimulation, apomorphine, and levodopa infusion in Parkinson’s disease. Mov Disord 2019; 34: 353–365.CrossRefGoogle ScholarPubMed
Jenkins, JR, Pearce, JMS. Paradoxical akinetic response to apomorphine in parkinsonism. J Neurol Neurosurg Psychiatry 1992; 55: 414–415.CrossRefGoogle ScholarPubMed
Joint Formulary Committee. British National Formulary (online). London: BMJ Group and Pharmaceutical Press. Accessed on 29 December 2022 via www.medicinescomplete.com.Google Scholar
Marras, C, Chaudhuri, KR, Titova, N, Mestre, TA. Therapy of Parkinson’s disease subtypes. Neurotherapeutics 2020; 17(4): 1366–1377.CrossRefGoogle ScholarPubMed
Martinez-Martin, P, Reddy, P, Antonini, A, Henriksen, T, Katzenschlager, R, Odin, P, Todorova, A, Naidu, Y, Tluk, S, Chandiramani, C, Martin, A, Chaudhuri, KR. Chronic subcutaneous infusion therapy with apomorphine in advanced Parkinson’s disease compared to conventional therapy: a real life study of non motor effect. J Parkinsons Dis 2011; 1(2): 197–203.CrossRefGoogle ScholarPubMed
Stocchi, F, De Pandis, MF, Delfino, FA, Anselmo, T, Frangillo, D. Transient atrial fibrillation after subcutaneous apomorphine bolus. Mov Disord 1996; 11: 584–585.CrossRefGoogle Scholar
Summary of Product Characteristics – APO-go PFS 5 mg/ml solution for infusion in pre-filled syringe. Britannia Pharmaceuticals Limited. Electronic Medicines Compendium: APO-go PFS 5 mg/ml solution for infusion in pre-filled syringe – summary of product characteristics (SmPC) – (emc). Accessed on 5 December 2022 via www.medicines.org.uk.Google Scholar

Save book to Kindle

To save this book to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×